Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Rhea-AI Summary
Vanda Pharmaceuticals (Nasdaq: VNDA) reported Q2 2026 total net product sales of $50.5 million, down 4% year-over-year, with Fanapt® up 23% to $36.0 million, PONVORY® up 12% to $7.9 million and HETLIOZ® down 66% to $5.6 million, excluding about $7.0 million of HETLIOZ® revenue expected to be recognized in Q3 2026.
NEREUS™ generated $1.0 million in its Q2 2026 U.S. launch quarter. Q2 loss before income taxes widened to $62.4 million, with net loss at $62.5 million. Cash, cash equivalents and marketable securities totaled $170.0 million at June 30, 2026; Vanda expects this, plus anticipated revenues, to fund operations through at least year-end 2027.
According to Vanda, BYSANTI™ received FDA approval in Q1 2026 with launch planned for H2 2026, Quimilza™ has a PDUFA target date of December 12, 2026, NEREUS™ became commercially available in Q2, and multiple Phase III readouts are expected in 2026–early 2027. Full-year 2026 total revenue guidance is $240–$290 million.
Positive
- Fanapt® Q2 2026 sales $36.0M, up 23% year-over-year
- PONVORY® Q2 2026 sales $7.9M, up 12% year-over-year
- Fanapt® prescriptions TRx up 31%, NBRx up 32% vs Q2 2025
- NEREUS™ launch $1.0M Q2 2026 sales from initial U.S. rollout
- Full-year 2026 revenue guidance $240–$290M reiterated
- Cash and securities $170.0M at June 30, 2026; expected runway through at least end of 2027
- BYSANTI™ FDA approval for bipolar I and schizophrenia; launch expected H2 2026
- Quimilza™ BLA under FDA review with Dec 12, 2026 PDUFA date
- Orphan and rare disease designations for Quimilza™ (GPP) and VCA-894A (CMT2S)
Negative
- Total Q2 2026 net product sales $50.5M, down 4% year-over-year
- HETLIOZ® Q2 2026 sales $5.6M, down 66% year-over-year (timing shift of ~$7M to Q3)
- Net loss Q2 2026 $62.5M vs $27.2M in Q2 2025
- Net loss H1 2026 $111.1M vs $56.7M in H1 2025
- Operating expenses H1 2026 $216.3M vs $182.2M in H1 2025
- Cash and securities decreased by $93.8M from Dec 31, 2025 to $170.0M
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 2026 earnings | Positive | -14.1% | Sales growth, FDA approval, product launch, and raised revenue guidance |
| Feb 11 | FY 2025 earnings | Negative | -17.6% | Large net loss and valuation allowance outweighed product and regulatory milestones |
| Jul 31 | Q2 2025 earnings | Negative | -8.8% | Declining HETLIOZ sales and net loss accompanied modest total-sales growth |
| May 07 | Q1 2025 earnings | Negative | -3.6% | Higher net loss and licensing payment offset product-sales growth |
| Feb 13 | FY 2024 earnings | Positive | -6.0% | Revenue growth and Fanapt momentum accompanied a smaller reported net loss |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings reactions were negative across all five prior events, with positively framed reports diverging from the subsequent price response.
Key Terms
pdufa regulatory
phase iii medical
gaap financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Fanapt® Q2 2026 net product sales increased
23% to$36.0 million 31% - Full-year 2026 total revenue guidance of
$240 -$290 - Cash totaled
$170.0 million - BYSANTI™ (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026
- Quimilza™ (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026
- NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026
- Results for three Phase III clinical trials expected by end of 2026:
- NEREUS™ (tradipitant) in vomiting in GLP-1,
- VQW-765 in social anxiety disorder
- HETLIOZ® (tasimelteon) in delayed sleep phase disorder
"We are pleased with the continued strong growth of Fanapt and the enthusiastic early response to NEREUS as it becomes available to patients. With BYSANTI approved and on track for launch in the second half of 2026, a December 2026 PDUFA date for Quimilza and multiple late-stage clinical trial results expected before year-end, we believe Vanda is well positioned for meaningful commercial expansion and pipeline value creation," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "As our Phase III programs, launch preparations, and commercial supply manufacturing near completion, we expect operating expenses to begin moderating later this year and more significantly in 2027. Our current resources, together with anticipated product revenues, provide a solid foundation to advance our objectives through at least the end of 2027."
Financial Highlights
- During 2025 and 2026, we have advanced multiple Phase III programs, continued execution on the commercialization of Fanapt® (iloperidone) and PONVORY® (ponesimod) and prepared for the commercial launches, including manufacturing commercial supplies, of NEREUS™ (tradipitant), BYSANTI™ (milsaperidone), and Quimilza™ (imsidolimab). These activities resulted in significantly increased operating expenses in 2025 and 2026. As these activities conclude, Vanda expects operating expenses to begin decreasing by the end of 2026 and more substantially throughout 2027. Based on its current cash position and anticipated revenues, Vanda expects to have sufficient resources to fund operations through at least the end of 2027.
Second Quarter of 2026
- Total net product sales were
$50.5 million 4% decrease compared to$52.6 million $7.0 million - Fanapt® net product sales were
$36.0 million 23% year-over-year. - HETLIOZ® (tasimelteon) net product sales were
$5.6 million 66% year-over-year, and do not include orders totaling approximately$7.0 million - PONVORY® net product sales were
$7.9 million 12% year-over-year. - NEREUSTM net product sales were
$1.0 million U.S . in Q2 2026 with the direct-to-consumer offering via the web portal nereus.us. Personal promotion is expected to commence later in 2026. - Loss before income taxes was
$62.4 million $34.9 million - Cash, cash equivalents and marketable securities (Cash) totaled
$170.0 million $32.3 million
First Six Months of 2026
- Total net product sales were
$102.2 million $102.6 million $7.0 million - Fanapt® net product sales were
$65.5 million 24% year-over-year. - HETLIOZ® net product sales were
$21.5 million 42% year-over-year, and do not include orders totaling approximately$7.0 million - PONVORY® net product sales were
$14.1 million 11% year-over-year. - NEREUSTM net product sales were
$1.0 million U.S . in Q2 2026 with the direct-to-consumer offering via the web portal nereus.us. Personal promotion is expected to commence later in 2026. - Loss before income taxes was
$110.8 million $72.3 million - Cash, cash equivalents and marketable securities (Cash) totaled
$170.0 million $93.8 million
Key Commercial Highlights
- Fanapt® saw continued strong momentum in Q2 2026, with total prescriptions (TRx)1 up
31% and new-to-brand prescriptions (NBRx)1 up32% versus Q2 2025. Since commercial expansion following the approval of bipolar disorder, Fanapt® has seen significant growth, with TRx1 up62% and NBRx1 up300% versus Q2 2024. - BYSANTI™ received
U.S . Food and Drug Administration (FDA) approval for the treatment of bipolar I disorder and schizophrenia in Q1 2026 and is expected to launch in the second half of 2026. BYSANTI™ is protected by data exclusivity through February 20, 2031 and multiple patents, the latest of which expires on May 31, 2044. - In May 2026, the early commercial launch of NEREUS™ was initiated with a direct-to-consumer offering via the web portal nereus.us. Personal promotion is expected to commence later in 2026.
Key Regulatory & Clinical Development Highlights
Upcoming Clinical Milestones
- Vanda's ongoing late-stage clinical studies are progressing rapidly and are expected to generate topline results in 2026 or early 2027, including:
- The Thetis Phase III study of NEREUS™ for the prevention of vomiting in patients receiving GLP-1 receptor agonist therapies, with results expected in 2026.
- The Phase III study of VQW-765 in the treatment of adults with social anxiety disorder, with results expected in 2026.
- The Phase III study of HETLIOZ® in the treatment of delayed sleep phase disorder (DSPD), with results expected in 2026.
- The Phase III study of BYSANTI™ as a once-daily adjunctive treatment for major depressive disorder (MDD), with results expected in the first half of 2027.
Other Updates
- The Biologics License Application (BLA) for Quimilza™ in Generalized Pustular Psoriasis (GPP) is under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026. The results of the pivotal clinical study were published in the April 28, 2026 issue of the New England Journal of Medicine (NEJM) Evidence2.
- In May 2026, Vanda announced that
Japan's Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation to Quimilza™ for the treatment of GPP. In July 2026, Vanda announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) had adopted a positive opinion recommending orphan drug designation for Quimilza™ for the treatment of GPP. - In July 2026, Vanda announced that the FDA had granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), a rare, serious, and progressive inherited neurological disorder.
- Vanda continues to progress the FDA formal hearing regarding HETLIOZ® for the treatment of jet lag disorder. The proceeding, a rare administrative hearing process granted after the D.C. Circuit set aside the FDA's prior refusal to approve the application, is advancing according to schedule and is expected to culminate in a five-day hearing before the Administrative Law Judge in December 2026.
GAAP Financial Results
Net loss was
Net loss was
2026 Financial Guidance
Vanda is reiterating its 2026 total revenue guidance and expects to achieve the following financial objectives in 2026:
Full Year 2026 Financial Objectives |
Full Year 2026 Guidance
|
Total revenues
| |
Fanapt® and BYSANTI™ net product sales*
| |
NEREUS™ net product sales
| |
Other net product sales
|
*Now includes contribution from both Fanapt® and BYSANTI™ based on expected BYSANTI™ launch timing. |
Conference Call
Vanda has scheduled a conference call for today, Wednesday, August 5, 2026, at 4:30 PM ET. During the call, Vanda's management will discuss the second quarter 2026 financial results and other corporate activities. Investors can call 1-888-596-4144 (domestic) or 1-646-968-2525 (international) and use passcode number 1843107. A replay of the call will be available on Wednesday, August 5, 2026, beginning at 8:30 PM ET and will be accessible until Wednesday, August 12, 2026 at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 1843107.
The conference call will be broadcast simultaneously on Vanda's website, www.vandapharma.com. Investors should click on the Investors tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda's website for a period of 30 days.
References
- IQVIA Prescription Data
- Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. NEJM Evidence 5, (2026).
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this press release, including, but not limited to, the guidance provided under "2026 Financial Guidance" above and statements regarding Vanda's expectations with respect to its ability to fund its operations through at least the end of 2027; the expected timing of the commercial launch of BYSANTI™ for the treatment of bipolar I disorder and schizophrenia; the anticipated timing of the completion of the FDA's review of the Quimilza™ BLA for the treatment of GPP; Vanda's clinical development plans and expected timelines for NEREUS™ in the prevention of vomiting induced by GLP-1 therapies, VQW-765 in the treatment of adults with social anxiety disorder, HETLIOZ® in the treatment of DSPD, and BYSANTI™ for the treatment of MDD; Vanda's expectations with respect to its commercial expansion and ability to create value from its product pipeline; Vanda's expectations with respect to its operating expense run rate through 2027; the anticipated timing of the commencement of personal promotion of NEREUS™; Vanda's continued pursuit of FDA approval of HETLIOZ® for the treatment of jet lag disorder and Vanda's expectations with respect to the HETLIOZ® evidentiary hearing; and Vanda's expectations with respect to the strength of its business are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's ability to continue to grow its business; Vanda's ability to reduce its operating expenses, conserve cash and generate enough revenue to fund its operations through at least the end of 2027; Vanda's ability to successfully execute the commercial launch of BYSANTI™ for the treatments of bipolar I disorder and schizophrenia in the second half of 2026; the FDA's ability to complete its review of, and reach a decision with respect to, the BLA for Quimilza™ by December 12, 2026; Vanda's ability to continue to advance its late-stage clinical development programs and to obtain regulatory approval for, and successfully commercialize, the late-stage products in development; Vanda's ability to complete the Phase III studies for NEREUS™ in the prevention of vomiting induced by GLP-1 therapies, VQW-765 in the treatment of adults with social anxiety disorder, and HETLIOZ® in the treatment of DSPD and receive the respective study results by the end of 2026; Vanda's ability to complete the Phase III study for BYSANTI™ for the treatment of MDD and receive results in the first half of 2027; Vanda's ability to commence personal promotion of NEREUS™ for the prevention of vomiting induced by motion in 2026; and the outcome of the administrative hearing process for HETLIOZ® for the treatment of jet lag disorder. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
VANDA PHARMACEUTICALS INC. | |||||||
Three Months Ended | Six Months Ended | ||||||
June 30 | June 30 | June 30 | June 30 | ||||
Revenues: | |||||||
Fanapt® net product sales | $ 35,989 | $ 29,294 | $ 65,549 | $ 52,839 | |||
HETLIOZ® net product sales | 5,576 | 16,192 | 21,523 | 37,064 | |||
PONVORY® net product sales | 7,935 | 7,104 | 14,146 | 12,728 | |||
NEREUSTM net product sales | 1,029 | — | 1,029 | — | |||
Total revenues | 50,529 | 52,590 | 102,247 | 102,631 | |||
Operating expenses: | |||||||
Cost of goods sold excluding amortization | 3,560 | 2,736 | 6,719 | 6,257 | |||
Research and development | 36,953 | 21,990 | 65,388 | 57,702 | |||
Selling, general and administrative | 71,838 | 64,616 | 140,199 | 114,700 | |||
Intangible asset amortization | 1,987 | 1,751 | 3,974 | 3,503 | |||
Total operating expenses | 114,338 | 91,093 | 216,280 | 182,162 | |||
Loss from operations | (63,809) | (38,503) | (114,033) | (79,531) | |||
Other income, net | 1,425 | 3,616 | 3,225 | 7,276 | |||
Loss before income taxes | (62,384) | (34,887) | (110,808) | (72,255) | |||
Provision (benefit) for income taxes | 129 | (7,680) | 272 | (15,554) | |||
Net loss | $ (62,513) | $ (27,207) | $ (111,080) | $ (56,701) | |||
Net loss per share, basic | $ (1.04) | $ (0.46) | $ (1.86) | $ (0.96) | |||
Net loss per share, diluted | $ (1.04) | $ (0.46) | $ (1.86) | $ (0.96) | |||
Weighted average shares outstanding, basic | 60,226,570 | 58,993,990 | 59,845,391 | 58,762,358 | |||
Weighted average shares outstanding, diluted | 60,226,570 | 58,993,990 | 59,845,391 | 58,762,358 | |||
VANDA PHARMACEUTICALS INC. | |||
June 30 | December 31 | ||
ASSETS | |||
Current assets: | |||
Cash and cash equivalents | $ 55,882 | $ 84,851 | |
Marketable securities | 114,147 | 178,996 | |
Accounts receivable, net | 59,692 | 54,578 | |
Inventory | 1,678 | 1,852 | |
Prepaid expenses and other current assets | 33,085 | 26,985 | |
Total current assets | 264,484 | 347,262 | |
Property and equipment, net | 2,578 | 2,248 | |
Operating lease right-of-use assets | 14,598 | 3,923 | |
Finance lease right-of-use assets | 6,772 | 7,343 | |
Intangible assets, net | 113,115 | 117,089 | |
Non-current inventory and other | 10,920 | 11,083 | |
Total assets | $ 412,467 | $ 488,948 | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |||
Current liabilities: | |||
Accounts payable and accrued liabilities | $ 69,994 | $ 68,297 | |
Product revenue allowances | 94,032 | 76,865 | |
Total current liabilities | 164,026 | 145,162 | |
Operating lease non-current liabilities | 15,027 | 2,991 | |
Finance lease non-current liabilities | 3,175 | 4,076 | |
Other non-current liabilities | 10,054 | 9,533 | |
Total liabilities | 192,282 | 161,762 | |
Stockholders' equity: | |||
Common stock | 60 | 59 | |
Additional paid-in capital | 725,933 | 721,264 | |
Accumulated other comprehensive income | 38 | 629 | |
Accumulated deficit | (505,846) | (394,766) | |
Total stockholders' equity | 220,185 | 327,186 | |
Total liabilities and stockholders' equity | $ 412,467 | $ 488,948 | |
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
Follow us on X @vandapharma
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-second-quarter-2026-financial-results-302844175.html
SOURCE Vanda Pharmaceuticals Inc.